NYSE:RMDMedical Equipment
ResMed (RMD) Margin Strength At 27.5% Tests Bearish Cost And GLP 1 Narratives
ResMed (RMD) has put up another solid quarter, with Q2 2026 revenue at about US$1.4b and basic EPS of US$2.69, while the trailing 12 month figures sit at US$5.4b of revenue and EPS of US$10.16. Over the past six reported quarters, revenue has moved from US$1,224.5m in Q1 2025 to US$1,422.8m in Q2 2026 and basic EPS has shifted from US$2.12 to US$2.69. This gives a clear view of the top line and per share earnings trend across the recent reporting run. With trailing 12 month earnings up 19%...